{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:59Z","timestamp":1789603859353,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2314-B-039-006-MY2"],"award-info":[{"award-number":["MOST 107-2314-B-039-006-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-039-025-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-039-025-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleos(t)ide analogue (NA) therapy remains unclear. We delineated the kinetics of HBsAg and analyzed its association with long-term treatment outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled 912 treatment-na\u00efve patients with chronic hepatitis B (CHB) who had received NA therapy for &amp;gt;12 months and analyzed the kinetic patterns through group-based trajectory models (GBTMs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median treatment duration for the entire cohort was 60.3 months. GBTMs revealed 4 patterns in patients achieving HBsAg loss (groups 1\u20134) in the study population and in patients achieving HBsAg &amp;lt;100\u2005IU\/mL among those with HBeAg-negative CHB with baseline HBsAg \u2265100\u2005IU\/mL (groups A\u2013D). Patients in groups 1 and A had the highest rates of HBsAg loss (22.2%, 6\/27) and of achieving HBsAg &amp;lt;100\u2005IU\/mL (47.5%, 56\/118), respectively. HBsAg &amp;lt;40\u2005IU\/mL and &amp;lt;400\u2005IU\/mL at 12 months of treatment predicted group 1 and group A membership among all patients and those with HBeAg-negative CHB, respectively. Multivariable Cox regression analysis identified HBsAg trajectory group (group 1 vs groups 3 and 4: hazard ratio [HR], 179.46; P &amp;lt; .001; group 2 vs groups 3 and 4: HR, 24.34; P &amp;lt; .001) and HBsAg decline (HR, 82.14; P &amp;lt; .001) as independent predictors of both HBsAg loss and achieving HBsAg &amp;lt;100\u2005IU\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Serum HBsAg trajectories and decline can predict HBsAg loss and the achievement of HBsAg &amp;lt;100\u2005IU\/mL in patients with CHB receiving long-term NA therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae699","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T07:52:51Z","timestamp":1732693971000},"source":"Crossref","is-referenced-by-count":5,"title":["Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-417X","authenticated-orcid":false,"given":"Wei-Fan","family":"Hsu","sequence":"first","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"Graduate Institute of Biomedical Science, China Medical University , Taichung ,","place":["Taiwan"]},{"name":"School of Chinese Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen-Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, MacKay Medical College , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"School of Chinese Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pang","family":"Su","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"School of Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"School of Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Tarn","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"School of Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-6086","authenticated-orcid":false,"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital , Taichung ,","place":["Taiwan"]},{"name":"School of Medicine, China Medical University , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2024122308173040800_ofae699-B1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2024122308173040800_ofae699-B2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2024122308173040800_ofae699-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"2024122308173040800_ofae699-B4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024122308173040800_ofae699-B5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"2024122308173040800_ofae699-B6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"2024122308173040800_ofae699-B7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","article-title":"Hepatitis B surface antigen seroclearance during chronic HBV infection","volume":"15","author":"Chu","year":"2010","journal-title":"Antivir Ther"},{"key":"2024122308173040800_ofae699-B8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: why and how to use it in 2011\u2014a core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J Hepatol"},{"key":"2024122308173040800_ofae699-B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"2024122308173040800_ofae699-B10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","article-title":"Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"204","author":"Chan","year":"2011","journal-title":"J Infect Dis"},{"key":"2024122308173040800_ofae699-B11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3851\/IMP1921","article-title":"Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients","volume":"16","author":"Chan","year":"2011","journal-title":"Antivir Ther"},{"key":"2024122308173040800_ofae699-B12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"2024122308173040800_ofae699-B13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","article-title":"Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift","volume":"13","author":"Liaw","year":"2019","journal-title":"Hepatol Int"},{"key":"2024122308173040800_ofae699-B14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"2024122308173040800_ofae699-B15","doi-asserted-by":"crossref","first-page":"42879","DOI":"10.1038\/srep42879","article-title":"Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B","volume":"7","author":"Peng","year":"2017","journal-title":"Sci Rep"},{"key":"2024122308173040800_ofae699-B16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"2024122308173040800_ofae699-B17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"Marcellin","year":"2014","journal-title":"J Hepatol"},{"key":"2024122308173040800_ofae699-B18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2024122308173040800_ofae699-B19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.13564","article-title":"Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy","volume":"38","author":"Hsu","year":"2018","journal-title":"Liver Int"},{"key":"2024122308173040800_ofae699-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1037\/1082-989X.4.2.139","article-title":"Analyzing developmental trajectories: a semi-parametric, group-based approach","volume":"4","author":"Nagin","year":"1999","journal-title":"Psychol Methods"},{"key":"2024122308173040800_ofae699-B21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0049124101029003005","article-title":"A SAS procedure based on mixture models for estimating developmental trajectories","volume":"29","author":"Jones","year":"2001","journal-title":"Sociol Methods Res"},{"key":"2024122308173040800_ofae699-B22","doi-asserted-by":"crossref","DOI":"10.4159\/9780674041318","volume-title":"Group-Based Modeling of Development","author":"Nagin","year":"2005"},{"key":"2024122308173040800_ofae699-B23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/infdis\/jiy697","article-title":"The incidence of hepatitis B surface antigen loss between hepatitis B e antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy","volume":"219","author":"Chen","year":"2019","journal-title":"J Infect Dis"},{"key":"2024122308173040800_ofae699-B24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"2024122308173040800_ofae699-B25","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024122308173040800_ofae699-B26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"},{"key":"2024122308173040800_ofae699-B27","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2024122308173040800_ofae699-B28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"2024122308173040800_ofae699-B29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","article-title":"Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy","volume":"60","author":"Papatheodoridis","year":"2014","journal-title":"J Hepatol"},{"key":"2024122308173040800_ofae699-B30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP3014","article-title":"Importance of IP-10 in hepatitis B","volume":"21","author":"Cornberg","year":"2016","journal-title":"Antivir Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae699\/60829782\/ofae699.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae699\/61136655\/ofae699.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae699\/61136655\/ofae699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T08:17:52Z","timestamp":1734941872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae699\/7909236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae699","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,11,27]]},"article-number":"ofae699"}}